Anand Kiran Parikh - 17 Feb 2026 Form 4 Insider Report for Sensei Biotherapeutics, Inc. (SNSE)

Role
Chief Operating Officer, Director
Signature
/s/ Anand Kiran Parikh
Issuer symbol
SNSE
Transactions as of
17 Feb 2026
Net transactions value
$0
Form type
4
Filing time
19 Feb 2026, 21:45:04 UTC
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Parikh Anand Kiran Chief Operating Officer, Director C/O SENSEI BIOTHERAPEUTICS, INC., 1405 RESEARCH BLVD, SUITE 125, ROCKVILLE /s/ Anand Kiran Parikh 19 Feb 2026 0002111813

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction SNSE Series B Preferred Stock Award +809,822 809,822 17 Feb 2026 Common Stock 810 Direct F1, F2, F3
transaction SNSE Employee Stock Option (right to buy) Award +92,533 92,533 17 Feb 2026 Common Stock 92,533 $1.16 Direct F4, F5
transaction SNSE Employee Stock Option (right to buy) Award +56,673 56,673 17 Feb 2026 Common Stock 56,673 $1.16 Direct F6, F7
transaction SNSE Employee Stock Option (right to buy) Award $0 +1,239,305 $0.000000 1,239,305 19 Feb 2026 Common Stock 1,239,305 $27.22 Direct F8
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each share of Series B Non-Voting Convertible Preferred Stock (the "Series B Preferred Stock") is convertible into 1,000 shares of Common Stock of Sensei Biotherapeutics, Inc. (the "Company"). The Preferred Stock has no expiration date.
F2 Received in exchange for 4,062,777 shares of common stock of Faeth Holdings Therapeutics, Inc. ("HoldCo") pursuant to an Agreement and Plan of Merger, dated February 17, 2026 (the "Merger Agreement"), by and among the Company, Sapphire First Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of the Company ("First Merger Sub"), Sapphire Second Merger Sub, LLC, a Delaware limited liability company and wholly owned subsidiary of the Company ("Second Merger Sub"), HoldCo and Faeth Therapeutics, LLC, a Delaware limited liability company and wholly owned subsidiary of HoldCo ("Faeth").
F3 Under the terms of the Merger Agreement, on February 17, 2026, First Merger Sub merged with and into HoldCo, with HoldCo surviving the first merger as a wholly owned subsidiary of the Company, and immediately following the first merger, HoldCo merged with and into Second Merger Sub, with Second Merger Sub surviving the second merger as a wholly owned subsidiary of the Company (such mergers, the "Merger"). Upon the closing of the Merger, shares of outstanding common stock of HoldCo were converted into the right to receive shares of the Company's Series B Preferred Stock in accordance with the Merger Agreement. Subject to certain conditions set forth in the Certificate of Designation of Preferences, Rights and Limitations of the Series B Preferred Stock, each share of Series B Preferred Stock is convertible into 1,000 shares of the Company's Common Stock ("Common Stock").
F4 Received in exchange for a stock option to acquire 464,222 shares of Faeth common stock with an exercise price of $0.23 per share pursuant to the Merger Agreement.
F5 Beginning August 1, 2022, the shares subject to the option vest in a series of forty-eight (48) successive equal monthly installments.
F6 Received in exchange for stock options to acquire an aggregate of 284,320 shares of Faeth common stock with an exercise price of $0.23 per share pursuant to the Merger Agreement.
F7 Immediately exercisable.
F8 25% of the shares shall vest on February 19, 2027, and the remaining shares shall vest in 36 equal monthly installments thereafter.